Physician profile
Andrew Sama
NPI 1992769608
$591,252.80
in general payments reported to CMS, 2019-2025
27 companies · $76K in 2025
The $76K reported for 2025 was more than what 91% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $91K · 2021: $48K · 2022: $71K · 2023: $84K · 2024: $87K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $141K · Royalty Or License: $68K · Travel and Lodging: $30K · Food and Beverage: $8,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $141,322.12 |
| Royalty Or License | $67,530.00 |
| Travel and Lodging | $29,969.98 |
| Food and Beverage | $8,835.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $201,351.43 | 2019-2024 | Viper, Expedium, T-Pal |
| Ortho Development Corporation | $124,278.05 | 2019-2025 | |
| Depuy Synthes Products, INC. | $84,031.04 | 2019-2025 | Conduit |
| Kuros Biosciences Ag | $60,545.99 | 2020-2025 | Magnetos |
| Clariance, INC. | $33,203.37 | 2019-2024 | Idys-Llif 3dti, Idys-Alif Zp 3dti, Erisma-Lp |
| Kuros Biosciences USA, INC | $22,718.40 | 2019-2025 | Magnetos |
| Clariance Sas | $20,496.51 | 2019-2025 | Idys-Alif Zp, Idys-Alif Zp, Enabling Technology |
| Expanding Innovations, INC. | $12,598.70 | 2024-2025 | X-Pac |
| Highridge Medical LLC | $12,075.15 | 2025 | Spine-None, Vital, Mobi-C Plug & Fit US |
| Augmedics INC. | $9,499.68 | 2022-2023 | Xvision |
| Ecential Robotics | $2,471.44 | 2025 | |
| Integrity Implants INC. | $2,137.57 | 2019-2022 | Flarehawk |
| Orthofix Medical, INC. | $1,870.99 | 2019-2023 | Osteostrand Plus |
| Mirus, LLC | $917.40 | 2019 | |
| 4web, INC. | $844.66 | 2020-2024 | Spine Truss System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neo Spine USA, INC. | $616.65 | 2025 | Neo Pedicle Screw System |
| Depuy Synthes Sales INC. | $614.97 | 2019-2024 | Teligen, Fibergraft Bg Morsels |
| Integrity Implants INC. Dba Accelus | $352.25 | 2023-2024 | |
| Pacira Pharmaceuticals Incorporated | $203.94 | 2023 | Exparel, Iovera, Zilretta |
| Nuvasive, INC. | $173.99 | 2023 | Simplify Cervical Artificial Disc |
| Stryker Corporation | $75.25 | 2024-2025 | Gamma |
| Embody, INC. | $46.22 | 2022 | |
| Centinel Spine, LLC | $34.02 | 2025 | Prodisc C |
| Spineart USA INC | $30.66 | 2024 | |
| Ricoh USA, INC | $25.09 | 2023 | |
| Arthrex, INC. | $24.00 | 2024 | |
| Suvon Surgical LLC | $15.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,078,046.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.